Jérôme van Biervliet

Director/Board Member at Exevir Bio BV

Health Technology

Health Services

Profile

Jérôme van Biervliet currently works at Waaroost NV, as Director from 2009, Augustine Therapeutics NV, as Director, and Exevir Bio BV, as Director.

Jérôme van Biervliet active positions

Companies	Position	Start
Exevir Bio BV Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.	Director/Board Member	-
Waaroost NV	Director/Board Member	19/02/2009
Augustine Therapeutics NV Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020.	Director/Board Member	-

All active positions of Jérôme van Biervliet

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jérôme van Biervliet's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	3
Exevir Bio BV Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.	Health Technology
Waaroost NV
Augustine Therapeutics NV Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020.	Health Services

See company connections